Pharmaceutical

Aytu BioPharma to commercialise Exxua for MDD in the US

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

Jun 11, 2025 - 06:00
Aytu BioPharma to commercialise Exxua for MDD in the US
Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.
Read the original article

Tags:

Previous Article

Podcast: AI and Supervised Machine Learning in Clinical Trials – Part 2

Next Article

American Society of Clinical Oncology (ASCO) Annual Meeting 2025

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships

STAT+: Biotech FogPharma raises $145 million in anticip...

Mar 2, 2024

First over-the-counter birth control pill in U.S. begins shipping to stores

First over-the-counter birth control pill in U.S. begin...

Mar 4, 2024

STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

STAT+: After Sarepta trial failure, families and doctor...

Nov 1, 2023